Eurofins Genomics Acquires Blue Heron Biotech, Expands Gene Synthesis Capabilities
The acquisition expands Eurofins Genomics’ gene portfolio while bolstering Blue Heron’s production capabilities.
In an Aug. 6, 2019 press release, Eurofins Genomics announced the completion of its acquisition of Blue Heron Biotech, a Bothell, WA-based gene synthesis company. The deal will bolster Blue Heron's production capabilities while expanding Eurofins Genomics’ gene portfolio into cloning and complex gene constructs. The acquisition will also strengthen Eurofins Genomics’ product portfolio in the synthetic biology market.
The companies share similar main product segments-oligonucleotides, sequencing, and synthetic genes. Eurofins Genomics’ product offerings include oligonucleotide synthesis, Sanger sequencing, next-generation sequencing, and gene synthesis. With the acquisition, the company can now provide holistic solutions to customers, including regulatory coverage for its products-ISO 13485, ISO 9001, CLIA, CAP, GLP, and FDA compliance for the manufacturing of cGMP oligonucleotides used in analyte specific reagent and in-vitro diagnostic products for the clinical industry.
Source: Eurofins Genomics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
